Thinking Through “Breakthrough”: Panel Discussion at the FDA/CMS Summit for Biopharma Executives
This article was originally published in RPM Report
During The RPM Report’s FDA/CMS Summit for Biopharma Executives December 10, Office of New Drugs Director John Jenkins and Genzyme Senior Policy Advisor Kay Holcombe discussed the dynamics of Breakthrough Therapy during a panel discussion moderated by The RPM Report’s Kate Rawson. Here is a transcript of that discussion.
You may also be interested in...
Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.
Vertex’ cystic fibrosis research is the recipient of the first two “Breakthrough” designations issued by FDA. That underscores the likelihood that the primary value of the new pathway will be as a badge for investors. And that’s probably a good thing.
The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.